Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer. The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small ...

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint ...

AI innovations, such as the ASCO Guidelines Assistant, enhance evidence-based decision-making by providing quick access to ...

Novel therapies targeting molecular pathways, including DLL3 and PARP inhibitors, show promise in improving SCLC survival outcomes. Tarlatamab, a DLL3-targeting bispecific T-cell engager, achieved a ...

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%.

Historically, non-small cell lung cancer (NSCLC) treatment involved three modalities: surgery, radiation therapy and chemotherapy. In the last two decades, the treatment landscape of NSCLC has greatly ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...